Lyra Therapeutics (LYRA) Income from Continuing Operations (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Income from Continuing Operations of 870000.0 in Q4 2025, up 85.46% on a QoQ basis from 5984000.0 in Q3 2025, and down 110.03% YoY from 8674000.0 in Q4 2024.
Lyra Therapeutics (LYRA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Income from Continuing Operations for 7 consecutive years, with 870000.0 the latest figure, recorded in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 870000.0, down 110.03% year-over-year; the trailing twelve-month figure through Dec 2025 was 22838000.0 (up 69.05% YoY), and the FY2025 annual result was 22838000.0, up 69.05% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 870000.0, up from 5984000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8674000.0 in Q4 2024, with the low at 48131000.0 in Q2 2024.
- A 5-year average of 13520600.0 and a median of 14120000.0 in 2021 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 157.23% in 2024, down 208.18% in 2024.
- Lyra Therapeutics' Income from Continuing Operations stood at 13690000.0 in 2021, then slipped by 3.89% to 14222000.0 in 2022, then retreated by 6.57% to 15156000.0 in 2023, then soared by 157.23% to 8674000.0 in 2024, then tumbled by 110.03% to 870000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 870000.0 (Q4 2025), 5984000.0 (Q3 2025), and 7437000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -870,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -870,000.00 |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -7.44 Mn |
| Mar 31, 2025 | -8.55 Mn |
| Dec 31, 2024 | 8.67 Mn |
| Sep 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -48.13 Mn |
| Mar 31, 2024 | -22.45 Mn |
| Dec 31, 2023 | -15.16 Mn |
| Sep 30, 2023 | -15.65 Mn |
| Jun 30, 2023 | -15.62 Mn |
| Mar 31, 2023 | -16.26 Mn |
| Dec 31, 2022 | -14.22 Mn |
| Sep 30, 2022 | -14.77 Mn |
| Jun 30, 2022 | -14.37 Mn |
| Mar 31, 2022 | -11.91 Mn |
| Dec 31, 2021 | -13.69 Mn |
| Sep 30, 2021 | -14.80 Mn |
| Jun 30, 2021 | -14.02 Mn |
| Mar 31, 2021 | -13.34 Mn |